Navigation Links
David Norton Appointed to TB Alliance's Board of Directors
Date:3/4/2013

NEW YORK, March 4, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing better, faster-acting, and affordable TB treatments, announces the election to its Board of Directors of David Norton , former Company Group Chairman of Global Pharmaceuticals for Johnson & Johnson (J&J). Mr. Norton brings to TB Alliance nearly 40 years of experience within the pharmaceutical sector, and is noted for his strategy in charting the growth of J&J's pharmaceuticals group.

"Tuberculosis research is on the verge of delivering incredible breakthroughs," said Mr. Norton. "I am committed to leveraging my experience in global product development and commercialization to enhance the impact of such crucial efforts and help stop the TB pandemic."

Throughout his career, Mr. Norton has helped lead J&J's efforts around research and development, commercial operations, licensing, and acquisitions. Now retired, he serves as Chairman of the Board of Directors of the American Foundation for Suicide Prevention. He is a member of the Board of Directors of Savient and recently served as interim CEO. Previously, Mr. Norton served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Alliance for Aging Research.

Dr. Carlos Morel , Chairman of the Board for TB Alliance and Director of the Center for Technological Development in Health (CDTS) of FIOCRUZ, remarked, "Mr. Norton's appointment to the TB Alliance's Board of Directors will expand the organization's knowledge — from developing new TB drug regimens to now ensuring widespread access to them. Mr. Norton's deep experience in shepherding new treatments to global markets will help the TB Alliance achieve its mission."

Tuberculosis (TB) is a global pandemic, killing someone approximately every 25 seconds — nearly 1.4 million in 2011 alone. The WHO estimates that two billion people — one third of the world's population — are infected with Mycobacterium tuberculosis (M.tb), the bacillus that causes the disease. Today's TB drug regimens take too long to cure, are complicated to administer, and can be toxic.  New drug regimens are critical to drastically reduce the global TB burden and to stop the growth and spread of drug-resistant forms of the disease.

About TB Alliance:
The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. The TB Alliance operates with funding from the Bill & Melinda Gates Foundation, Irish Aid , UK aid, UNITAID, National Institute of Allergy and Infectious Disease, the United States Agency for International Development, and the United States Food and Drug Administration, and the United States AIDS Clinical Trials Group. For more information, please visit tballiance.org.

Contact:

Joanna Breitstein
TB Alliance
(m) 646.616.8613
Joanna.breitstein@tballiance.org


'/>"/>
SOURCE TB Alliance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. David F. Harty Joins Systech International as Vice President
2. Dr. David Brailer and Stephen Dubner Keynotes for NYeC 2012 Digital Health Conference
3. WebMD Taps David C. Marek to Assume Consumer Leadership Role
4. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
5. Alliqua Names David Johnson Executive Chairman of Aquamed Technologies and Member of Alliqua Board of Directors
6. Herb Baer Appointed President of Polar USA
7. New Executive Vice President Commercial Appointed
8. Israel Makov Appointed Chairman of Sun Pharma Board
9. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
10. Neal K. Long appointed as Chief Executive Officer at Cardiac Science
11. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , 8 de dezembro de 2016  A Mederi Therapeutics Inc ... Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and broadcast ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... AMSTERDAM , December 8, 2016 Information ... TM metrics in Scopus , the world,s largest ... free access to comprehensive metrics for journals from over 5,000 publishers. ... publish, which journals to subscribe to and when to adjust a ... , , ...
Breaking Medicine Technology:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... planning services from offices headquartered in Jefferson County, is announcing the launch of ... in Birmingham. , The number of homeless women and children in Birmingham has ...
(Date:12/8/2016)... Payne, AL (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial consulting services to residential and commercial clients in the ... awareness and support for Nobis Works. , Since 1977, Nobis Works has built ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... celebrating the passage of the most comprehensive mental health systems reform legislation in ... support of the President, and the commitment of our elected officials to improving ...
(Date:12/7/2016)... LAKE CITY, UTAH (PRWEB) , ... December 07, ... ... productivity, today announced the release of Smart Device Remote Control through a new ... management across all platforms and strengthens its mobile solutions to help businesses maximize ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to ... analyzed data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical ... the need to operate in a GLP (Good Laboratory Practice) fashion. , With features ...
Breaking Medicine News(10 mins):